In her role at bluebird bio, Molly leads internal and partnered R&D programs for CAR T cell products and is responsible for research contribution to cellular process improvements and correlative sciences for clinical programs. Dr. Perkins contributed to research candidate nomination and translational bioassays for bluebird’s lead anti-BCMA CAR T program, bb2121, which is currently in pivotal studies. She co-led the research program and translational bioassay development for bb21217, bluebird’s next-generation anti-BCMA CAR T therapy, which is currently in Phase 1 studies. Dr. Perkins earned her B.A. from Harvard University, her M.Sc. from Cold Spring Harbor Laboratory, and her D.Phil. from Oxford University and completed a post-doctoral fellowship in T cell immunology at the National Institutes of Health (NIH). She is an author on a dozen peer-reviewed publications focused on defining effective human T cell responses and applying these findings to novel therapeutics.